miR-92a：A molecular CRC specific diagnostic marker
MiR-92a (microRNA-92a), a small non-coding RNA, is a newly discovered biomarker with high sensitivity and specificity to CRC. It promotes cell proliferation and migration of colorectal cancer cells by targeting PTEN, KLF4 and downstream p21 genes. Multiple studies found characteristically increased miR-92a level in patients’ stool specimen with CRC or CRC lesions. REColonTM works through detecting miR-92a level directly from CRC cells shed from lining of human colon and eventually excreted in the stool.
A comparative analysis is made between colonoscopy and REColonTM tests of in total 1,241 CRC and normal cases, REColonTM achieves 71.76% sensitivity and 90.07% specificity for CRC diagnosis.
71.76% Sensitivity，90.23% Specificity
REColonTM | Colonoscopy | Total | |
Positive | Negative | ||
Positive | 244 | 88 | 332 |
Negative | 96 | 813 | 909 |
Total | 340 | 901 | 1,241 |
Ø REColonTM Diagnostic Accuracy : 84.96%（1,057/1,241）
Ø Sensitivity：71.76% (244/340)
Ø Specificity：90.23% (813/901)
Non-specificity Reaction Evaluation
Non-CRC Group | miR-92 neg（-） | miR-92a pos（+） | Specificity | Non-CRC group | miR-92 neg（-） | miR-92a pos（+） | Specificity |
Pancreatic Cancer （20 cases） | 20 | 0 | 100% | Enteritis （45 cases） | 42 | 3 | 93.33% |
Bile Duct Cancer （20 cases） | 19 | 1 | 95.00% | Colitis （29 cases） | 27 | 2 | 93.10% |
Liver Cancer （20 cases） | 19 | 1 | 95.00% | Peptic ulcer （24 cases） | 23
| 1 | 95.83% |
Oral Cancer （20 cases） | 19 | 1 | 95.00% | Appendicitis （20 cases） | 19 | 1 | 95.00% |
Esophageal Cancer （20 cases） | 20 | 0 | 100% | Gastritis （20例） | 19 | 1 | 95.00% |
Gastric Cancer （25 cases） | 23 | 2 | 92.00% | ||||
|
|
